|
Hypertensive disease
|
0.160 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest high BMI increases the effect of the blood pressure-increasing allele at rs1458038 near FGF5, further highlighting the importance of obesity prevention in reducing hypertension risk.
|
25618516 |
2015 |
|
Hypertensive disease
|
0.160 |
GeneticVariation
|
group |
BEFREE |
Our results implicate variation in FGF5 and ZNF652 gene upstream regions with altered susceptibility to hypertension in Han Chinese.
|
20542020 |
2010 |
|
Hypertensive disease
|
0.160 |
GeneticVariation
|
group |
BEFREE |
The present study confirmed the significant association of ATP2B1 rs17249754 with risk of hypertension among Chinese children, but failed to replicate the association of CSK rs1378942, MTHFR rs1801133, CYP17A1 rs1004467, STK39 rs3754777 and FGF5 rs16998073 with BP/risk of hypertension.
|
23759979 |
2014 |
|
Hypertensive disease
|
0.160 |
GeneticVariation
|
group |
BEFREE |
The present meta-analysis indicated significant associations of both CYP17A1 rs11191548 and FGF5 rs16998073 polymorphisms with hypertension susceptibility in East Asians.
|
22959498 |
2013 |
|
Hypertensive disease
|
0.160 |
GeneticVariation
|
group |
BEFREE |
The genetic risk score, calculated as the sum of BP-increasing alleles of FGF5-rs16998073, CYP17A1-rs11191548, CYP17A1-rs1004467 and MTHFR-rs17367504, was significantly associated with increased SBP (1.16 mmHg/allele, P = 9.01E-5), DBP (0.51 mmHg/allele, P = 4.40E-4) and hypertension risk (OR = 1.22/allele, P = 2.74E-7).
|
20852445 |
2011 |
|
Hypertensive disease
|
0.160 |
Biomarker
|
group |
BEFREE |
In particular, FGF5 is associated with high blood pressure.
|
24521867 |
2014 |
|
Alopecia, Male Pattern
|
0.110 |
Biomarker
|
disease |
BEFREE |
The 63 loci explain ∼39% of the phenotypic variance in MPB and highlight several plausible candidate genes (FGF5, IRF4, DKK2) and pathways (melatonin signalling, adipogenesis) that are likely to be implicated in the key-pathophysiological features of MPB and may represent promising targets for the development of novel therapeutic options.
|
28272467 |
2017 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> FGF5 was significantly upregulated in OS tissues and cells, and closely associated with poor differentiation, larger tumor size, lymph node metastasis, and advanced TNM stage.
|
31372048 |
2019 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
BC patients in the FGF5 low-expression group were correlated with better clinical characteristics, including tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, NPI criteria and Veridex signature, DMFS, TDM, and DFS compared with those in the FGF5 high-expression cohort.
|
29804124 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, our data indicated that miR-567 may function as a tumor suppressor by negatively regulating FGF5 and be potential therapeutic targets for the treatment of OS.
|
29743851 |
2018 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
FGF-5 was found to be expressed in the neonatal brain and in 3 of the 13 human tumor cell lines examined.
|
3211147 |
1988 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In an <i>in vivo</i> experiment in immunocompromised mice, human melanoma xenografts overexpressing FGF5 showed enhanced tumor growth, a higher Ki-67 proliferation index, decreased apoptosis and enhanced angiogenesis.
|
29152117 |
2017 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Two secreted factors whose roles in the constitutive activation of NFkappaB are not well defined were investigated further as pure proteins: transforming growth factor beta2 (TGFbeta2) and fibroblast growth factor 5 (FGF5) were both highly expressed in some mutant clones and tumor cell lines, each activated NFkappaB alone, and the combination was synergistic.
|
14676835 |
2004 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In addition, migration and invasion-associated proteins (E-cadherin, matrix metalloproteinase-2 [MMP-2], and MMP-9) and epithelial mesenchymal transition markers (N-cadherin, vimentin, snail, and slug) were also regulated by FGF5 siRNA treatment.
|
30520094 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Here we demonstrate that ectopic overexpression of FGF5 in human melanoma cells with low endogenous FGF5 expression increased clonogenicity and invasion but not short-term growth <i>in vitro</i>.
|
29152117 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The bone metastasis-related genes encode secretory and cell surface proteins implicated in bone-homing (CXCR4), angiogenesis (CTGF and FGF5), invasion (MMP-1 and ADAMTS1), and osteoclast recruitment (IL11).
|
22120474 |
2012 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
We also showed that overexpression of FGF5 could partially antagonize the suppressive effects of miR-567 on OS cell proliferation, migration and invasion.
|
29743851 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Our results suggest that FGF5 is an independent protective factor for BC patients.
|
29804124 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
FGF5 is expressed in melanoma and enhances malignancy <i>in vitro</i> and <i>in vivo</i>.
|
29152117 |
2017 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Gene set enrichment analysis on The Cancer Genome Atlas dataset showed that the Kyoto Encyclopedia of Genes and Genomes (KEGG) cell cycle and vascular endothelial growth factor (VEGF) pathways were correlated with FGF5 expression, which was further confirmed in NSCLC cells by Western blot analysis.
|
30520094 |
2018 |
|
Obesity
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest high BMI increases the effect of the blood pressure-increasing allele at rs1458038 near FGF5, further highlighting the importance of obesity prevention in reducing hypertension risk.
|
25618516 |
2015 |
|
Obesity
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The genetic risk score (GRS), based on these three SNPs (CSK rs1378942, MTHFR rs1801133, FGF5 rs16998073), showed a positive association with risk of obesity (OR = 1.18, 95% CI 1.09-1.28, P = 7.60 × 10<sup>-5</sup>).
|
30217759 |
2018 |
|
Osteosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> FGF5 was significantly upregulated in OS tissues and cells, and closely associated with poor differentiation, larger tumor size, lymph node metastasis, and advanced TNM stage.
|
31372048 |
2019 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our data indicated that miR-567 may function as a tumor suppressor by negatively regulating FGF5 and be potential therapeutic targets for the treatment of OS.
|
29743851 |
2018 |